Granisetron Aurobindo (Granisetron)

Granisetron Aurobindo is indicated for the prevention of nausea and vomiting in specific clinical situations. It is commonly prescribed to manage symptoms caused by chemotherapy and to reduce postoperative nausea and vomiting.

• Prevention of acute chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of delayed chemotherapy‑induced nausea and vomiting following highly emetogenic regimens.
• Prevention of postoperative nausea and vomiting (PONV) after general anesthesia.
• Adjunct therapy for patients receiving radiation therapy who experience nausea.
• Use in combination with other antiemetics for enhanced control of emesis.
• Consideration for off‑label use in pediatric oncology under specialist supervision.

The safety profile of granisetron includes both frequently observed and less common adverse events.

Common

• Headache – mild to moderate pain often occurring shortly after dosing.
• Constipation – reduced bowel movements that may be relieved with dietary fiber.
• Diarrhea – loose stools that are usually transient.
• Fatigue – feeling of tiredness without a clear cause.
• Dizziness – light‑headed sensation, especially when standing quickly.

Serious

• Allergic reactions – rash, itching, swelling, or hives that require medical attention.
• Cardiac arrhythmias – rare irregular heartbeats that may need monitoring.
• Serotonin syndrome – potentially life‑threatening condition when used with other serotonergic drugs.

Before prescribing Granisetron Aurobindo, clinicians should evaluate patient history and potential risk factors. Specific precautions help minimize adverse outcomes and ensure appropriate use.

• Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with prolonged QT interval or cardiac conduction disorders.
• Evaluate renal or hepatic impairment, as dose adjustment may be required.
• Avoid use during the first trimester of pregnancy unless benefits outweigh risks.
• Monitor for signs of serotonin syndrome when combined with serotonergic agents.
• Consider age‑related dosing adjustments in elderly patients.
• Review concomitant medications that may prolong the QT interval.

Granisetron can interact with other medicines, affecting its efficacy or safety profile. Understanding these interactions assists clinicians in making informed prescribing decisions.

Avoid

• Concurrent use with other 5‑HT3 antagonists, which may increase risk of cardiac effects.
• Co‑administration with drugs that markedly prolong the QT interval (e.g., certain antiarrhythmics).

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, or tramadol, due to serotonin syndrome risk.
• Antifungal azoles (e.g., ketoconazole) that inhibit CYP3A4, potentially raising granisetron levels.
• Antiemetics that also affect cardiac conduction, requiring ECG monitoring.
• Electrolyte disturbances (hypokalemia, hypomagnesemia) that can exacerbate QT prolongation.